Pinnacle Associates’s Bicycle Therapeutics BCYC Stock Holding History

Pinnacle Associates’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$591K	Sell	160,551 -29,439	-15%	-$119K	0.01%	641
2026 Q2	$806K	Buy	189,990 +4,580	+2%	+$21K	0.01%	583
2026 Q1	$860K	Sell	185,410 -5,070	-3%	-$29K	0.01%	546
2025 Q4	$1.35M	Sell	190,480 -6,138	-3%	-$45.3K	0.02%	469
2025 Q3	$1.52M	Buy	196,618 +24,665	+14%	+$186K	0.02%	441
2025 Q2	$1.2M	Sell	171,953 -42,325	-20%	-$337K	0.02%	472
2025 Q1	$1.82M	Sell	214,278 -12,464	-5%	-$147K	0.03%	391
2024 Q4	$3.17M	Buy	+226,742	New	+$4.86M	0.04%	303
2024 Q3	–	Sell	-242,001	Closed	-$4.9M	–	806
2024 Q2	$4.9M	Buy	242,001 +161,911	+202%	+$3.66M	0.08%	245
2024 Q1	$1.99M	Buy	+80,090	New	+$1.7M	0.03%	371

Other funds holding BCYC

Woodstock Corp Boston, Massachusetts $1.24B AUM 22.02% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Pinnacle Associates's BCYC Position: Q3 2026 in Review

Pinnacle Associates reduced its Bicycle Therapeutics (BCYC) stake by 15% in Q3 2026, selling an estimated $119K and leaving 160,551 shares worth $591K. The position accounts for 0.01% of the portfolio, ranked #641.

Pinnacle Associates first reported a position in BCYC in Q1 2024 and has held it in 10 quarters since. The position peaked at $4.9M in Q2 2024. 4 funds tracked by Wall St. Rank hold BCYC as of Q3 2026.

Pinnacle Associates held 160,551 shares of Bicycle Therapeutics worth $591K as of Q3 2026.
Pinnacle Associates sold 29,439 Bicycle Therapeutics shares in Q3 2026, an estimated $119K.
Bicycle Therapeutics made up 0.01% of Pinnacle Associates's portfolio in Q3 2026, its #641 holding.
Pinnacle Associates first reported a position in Bicycle Therapeutics in Q1 2024 and has held it in 10 quarters since.
Pinnacle Associates's Bicycle Therapeutics position peaked at $4.9M in Q2 2024.
4 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2026.

Based on Pinnacle Associates's 13F filing for Q3 2026, filed 20 Oct 2026.